Browse result page of CancerPDF Database
Please click on CancerPDF_ID for detailed information about peptide.
| CancerPDF_ID | Peptide seq | Protein Name | Fluid | Mass/Z | Profiling Technique | Cancer Type | Expression Regulation | PUBMED ID |
|---|---|---|---|---|---|---|---|---|
| CancerPDF_ID958 | NA | NA | Serum | 5907.39 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID961 | NA | NA | Serum | 4210.93 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID962 | NA | NA | Serum | 9300.76 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID963 | NA | NA | Serum | 2660.82 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID964 | NA | NA | Serum | 7772.38 | MALDI-TOF | Colorectal cancer | Upregulated and considered as candidate biomarker | 23091368 |
| CancerPDF_ID966 | NA | NA | Serum | 1617.78 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID968 | NA | NA | Serum | 4645.43 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID969 | NA | NA | Serum | 4091.82 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID972 | NA | NA | Serum | 1466.77 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID974 | NA | NA | Serum | 1546.58 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID975 | NA | NA | Serum | 3241.4 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID976 | NA | NA | Serum | 5338.71 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID978 | NA | NA | Serum | 2952.94 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID979 | NA | NA | Serum | 3952.53 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID980 | NA | NA | Serum | 4965.34 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID981 | NA | NA | Serum | 4054.81 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID982 | NA | NA | Serum | 2863.08 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID983 | NA | NA | Serum | 3263.36 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID984 | NA | NA | Serum | 3883.56 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID985 | NA | NA | Serum | 1866.35 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID986 | NA | NA | Serum | 1520.21 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID987 | NA | NA | Serum | 1450.62 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID988 | NA | NA | Serum | 4268.26 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID989 | NA | NA | Serum | 4123.72 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID990 | NA | NA | Serum | 5868.38 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID991 | NA | NA | Serum | 3192.38 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID992 | NA | NA | Serum | 2884.13 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID993 | NA | NA | Serum | 4073.6 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID994 | NA | NA | Serum | 2932.84 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID995 | NA | NA | Serum | 2105.88 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID996 | NA | NA | Serum | 4169.7 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID997 | NA | NA | Serum | 2900.31 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID999 | NA | NA | Serum | 2769.91 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID1000 | NA | NA | Serum | 1540.23 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID1001 | NA | NA | Serum | 3935.5 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID1002 | NA | NA | Serum | 1779.25 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID1003 | NA | NA | Serum | 2644.78 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID1005 | NA | NA | Serum | 5755.96 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID1006 | NA | NA | Serum | 4155.14 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID1007 | NA | NA | Serum | 5636.48 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID1008 | NA | NA | Serum | 2723.35 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID1009 | NA | NA | Serum | 1207.42 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID1011 | NA | NA | Serum | 1351 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID1013 | NA | NA | Serum | 2545.55 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID1014 | NA | NA | Serum | 2877.97 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID1015 | NA | NA | Serum | 4110.58 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID1016 | NA | NA | Serum | 5066.24 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID1017 | NA | NA | Serum | 4676.49 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID1018 | NA | NA | Serum | 2046.31 | MALDI-TOF | Colorectal cancer | Upregulated in cancer vs normal | 23091368 |
| CancerPDF_ID1028 | GSESGIFTNTKESSSHHPGIAEFPSRG | Fibrinogen alpha chain | Serum | 2816.25 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) = 68, 223 and 1 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1029 | SSSYSKQFTSSTSYNRGDSTFES | Fibrinogen alpha chain | Serum | 2553.01 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) = 1.35, 1.31 and 1.5 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1031 | SSSYSKQFTSSTSYNRGDSTFESKSY | Fibrinogen alpha chain | Serum | 2931.29 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Downregulated in bladder cancer and upregulated in prostate cancer vs normal with Ratio of median intensity (patients/Controls) = 1.24, 0.13 and 0.97 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1037 | DEAGSEADHEGTHSTKRGHAKSRPV | Fibrinogen alpha chain | Serum | 2659.03 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) = 1.37, 1.18 and 2.45 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1040 | IHWESASLL | Complement C3f | Serum | 1055.6 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) = 227, 1051 and 1 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1041 | RIHWESASLL | Complement C3f | Serum | 1211.7 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =7.86, 10.8 and 0.01 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1049 | SSKITHRIHWESASL | Complement C3f | Serum | 1751.88 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1.82, 5.7 and 1.36 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1050 | NGFKSHALQLNNR | Complement C4 precursor | Serum | 1498.91 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1, 809 and 1 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1051 | NGFKSHALQLNNRQ | Complement C4 precursor | Serum | 1626.85 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1.09, 0.88 and 2.78 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1052 | NGFKSHALQLNNRQI | Complement C4 precursor | Serum | 1739.93 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =0.75, 0.66 and 2.75 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1053 | NGFKSHALQLNNRQIR | Complement C4 precursor | Serum | 1895.99 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1.27, 3.33 and 2.95 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1055 | GLEEELQFSLGSKINVKVGGNS | Complement C4 precursor | Serum | 2305.2 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =3.75, 2.56 and 3.49 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1056 | GLEEELQFSLGSKINVKVGGNSKGTL | Complement C4 precursor | Serum | 2704.13 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =61, 49 and 133 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1059 | HAAYHPF | Inter-alpha-trypsin inhibitor heavy chain H4 | Serum | 842.4 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in Prostate cancer vs normal,Downregulated in Bladder cancer vs normal with Ratio of median intensity (patients/Controls) =1.49, 0.01 and 1.04 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1060 | GLPGPPDVPDHAAYHPF | Inter-alpha-trypsin inhibitor heavy chain H5 | Serum | 1786.86 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =2.39, 2.88 and 2.3 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1062 | SRQLGLPGPPDVPDHAAYHPF | Inter-alpha-trypsin inhibitor heavy chain H7 | Serum | 2271.14 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =4.58, 2.64 and 1.46 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1063 | SSRQLGLPGPPDVPDHAAYHPF | Inter-alpha-trypsin inhibitor heavy chain H8 | Serum | 2358.09 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =100, 73 and 531 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1065 | PGVLSSRQLGLPGPPDVPDHAAYHPF | Inter-alpha-trypsin inhibitor heavy chain H10 | Serum | 2724.48 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1.75, 6.17 and 1.64 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1066 | MNFRPGVLSSRQLGLPGPPDVPDHAAYHPF | Inter-alpha-trypsin inhibitor heavy chain H11 | Serum | 3272.5 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1, 1277 and 1 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1067 | QAGAAGSRMNFRPGVLSSRQLGLPGPPDVPDHAAYHPF | Inter-alpha-trypsin inhibitor heavy chain H12 | Serum | 3970.97 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1, 957 and 1 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1068 | QLGLPGPPDVPDHAAYHPFR | Inter-alpha-trypsin inhibitor heavy chain H13 | Serum | 2183.91 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1.71, 1.79 and 2.83 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1069 | HAAYHPFR | Inter-alpha-trypsin inhibitor heavy chain H14 | Serum | 998.45 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =121, 256 and 147 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1070 | NVHSGSTFFKYYLQGAKIPKPEASFSPR | Inter-alpha-trypsin inhibitor heavy chain H15 | Serum | 3156.52 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =3.43, 10.68 and 1.33 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1071 | NVHSAGAAGSRMNFRPGVLSS | PRO1851(ITIH4 splice variant) | Serum | 2115.01 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =3.22, 12.23 and 10.61 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1072 | ATEHLSTLSEKAKPALEDL | Apolipoprotein A-I | Serum | 2052.89 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =105, 306 and 1 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1073 | QGLLPVLESFKVSFLSALEEYTKKLNTQ | Apolipoprotein A-I | Serum | 3182.46 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =0.74, 6.36 and 1 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1074 | VSFLSALEEYTKKLNTQ | Apolipoprotein A-I | Serum | 1971.16 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1, 641 and 1 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1077 | ISASAEELRQRLAPLAEDVRGNL | Apolipoprotein A-IV | Serum | 2508.16 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1.38, 1.2 and 7.96 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1078 | SLAELGGHLDQQVEEF | Apolipoprotein A-IV | Serum | 1771.81 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =148, 220 and 1 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1080 | GNTEGLQKSLAELGGHLDQQVEEFR | Apolipoprotein A-IV | Serum | 2755.2 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1.11, 12.37 and 1.22 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1081 | SLAELGGHLDQQVEEFR | Apolipoprotein A-IV | Serum | 1927.94 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =79, 671 and 1 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1084 | AATVGSLAGQPLQERAQAWGERL | Apolipoprotein E | Serum | 2409.13 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =97, 2124 and 109 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1085 | AATVGSLAGQPLQERAQAWGERLR | Apolipoprotein E | Serum | 2565.45 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1, 902 and 1 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1086 | HFFFPK | Clusterin precursor | Serum | 822.41 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1.15, 4.66 and 0.76 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1087 | HFFFPKSRIV | Clusterin precursor | Serum | 1277.71 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =251, 1406 and 1 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1092 | NLGHGHKHERDQGHGHQ | HMW Kininogen | Serum | 1943.88 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1.58, 141 and 1 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1093 | KHNLGHGHKHERDQGHGHQ | HMW Kininogen | Serum | 2209.08 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1.72, 2.07 and 1.56 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1095 | AVPPNNSNAAEDDLPTVELQGVVPR | Factor XIIIa | Serum | 2602.15 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =2.84, 2.3 and 4.73 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1096 | ALGISPFHEHAEVVFTANDSGPR | Transtherin precursor (‘prealbumin’) | Serum | 2451.11 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =0.02, 1.17 and 3.07 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1172 | NA | NA | Serum | 3279.25 | MALDI-TOF | Lung cancer | Upregulated in cancer vs normal with average expression of peptide in cancer 4.22 and in normal 1.87 | 21082738 |
| CancerPDF_ID1173 | NA | NA | Serum | 2881.24 | MALDI-TOF | Lung cancer | Upregulated in cancer vs normal with average expression of peptide in cancer 3.01 and in normal 1.47 | 21082738 |
| CancerPDF_ID1175 | NA | NA | Serum | 3208.59 | MALDI-TOF | Lung cancer | Upregulated in cancer vs normal with average expression of peptide in cancer 2.57 and in normal 1.56 | 21082738 |
| CancerPDF_ID1176 | NA | NA | Serum | 1741.48 | MALDI-TOF | Lung cancer | Upregulated in cancer vs normal with average expression of peptide in cancer 4.13 and in normal 2.11 | 21082738 |
| CancerPDF_ID1177 | NA | NA | Serum | 6047.99 | MALDI-TOF | Lung cancer | Upregulated in cancer vs normal with average expression of peptide in cancer 1.3 and in normal 0.86 | 21082738 |
| CancerPDF_ID1179 | NA | NA | Serum | 5248.05 | MALDI-TOF | Lung cancer | Upregulated in cancer vs normal with average expression of peptide in cancer 1.38 and in normal 1.02 | 21082738 |
| CancerPDF_ID1180 | NA | NA | Serum | 5079.93 | MALDI-TOF | Lung cancer | Upregulated in cancer vs normal with average expression of peptide in cancer 1.4 and in normal 0.89 | 21082738 |
| CancerPDF_ID1186 | NA | NA | Serum | 5293.03 | MALDI-TOF | Lung cancer | Upregulated in cancer vs normal with average expression of peptide in cancer 1.52 and in normal 0.91 | 21082738 |
| CancerPDF_ID1187 | NA | NA | Serum | 4530.17 | MALDI-TOF | Lung cancer | Upregulated in cancer vs normal with average expression of peptide in cancer 1.23 and in normal 0.69 | 21082738 |
| CancerPDF_ID1188 | NA | NA | Serum | 1887.19 | MALDI-TOF | Lung cancer | Upregulated in cancer vs normal with average expression of peptide in cancer 2.6 and in normal 2.15 | 21082738 |
| CancerPDF_ID1189 | NA | NA | Serum | 1082.52 | MALDI-TOF | Lung cancer | Upregulated in cancer vs normal with average expression of peptide in cancer 4.48 and in normal 1.68 | 21082738 |
| CancerPDF_ID1190 | NA | NA | Serum | 2770.03 | MALDI-TOF | Lung cancer | Upregulated in cancer vs normal with average expression of peptide in cancer 6.6 and in normal 4.07 | 21082738 |
| CancerPDF_ID1194 | NA | NA | Serum | 1331.23 | MALDI-TOF | Lung cancer | Upregulated in cancer vs normal with average expression of peptide in cancer 2.86 and in normal 2.14 | 21082738 |
| CancerPDF_ID1195 | NA | NA | Serum | 1350.83 | MALDI-TOF | Lung cancer | Upregulated in cancer vs normal with average expression of peptide in cancer 2.73 and in normal 1.75 | 21082738 |
| CancerPDF_ID1196 | NA | NA | Serum | 1066.34 | MALDI-TOF | Lung cancer | Upregulated in cancer vs normal with average expression of peptide in cancer 4.62 and in normal 2.44 | 21082738 |
| CancerPDF_ID1198 | NA | NA | Serum | 2545.94 | MALDI-TOF | Lung cancer | Upregulated in cancer vs normal with average expression of peptide in cancer 1.96 and in normal 1.37 | 21082738 |
| CancerPDF_ID1200 | NA | NA | Serum | 2046.59 | MALDI-TOF | Lung cancer | Upregulated in cancer vs normal with average expression of peptide in cancer 3.67 and in normal 2.79 | 21082738 |
| CancerPDF_ID1201 | NA | NA | Serum | 1866.51 | MALDI-TOF | Lung cancer | Upregulated in cancer vs normal with average expression of peptide in cancer 6.58 and in normal 3.02 | 21082738 |
| CancerPDF_ID1203 | NA | NA | Serum | 1450.73 | MALDI-TOF | Lung cancer | Upregulated in cancer vs normal with average expression of peptide in cancer 5.64 and in normal 2.81 | 21082738 |
| CancerPDF_ID1204 | NA | NA | Serum | 3061.3 | MALDI-TOF | Lung cancer | Upregulated in cancer vs normal with average expression of peptide in cancer 3.12 and in normal 1.18 | 21082738 |
| CancerPDF_ID1205 | NA | NA | Serum | 4712.02 | MALDI-TOF | Lung cancer | Upregulated in cancer vs normal with average expression of peptide in cancer 1.03 and in normal 0.68 | 21082738 |
| CancerPDF_ID3339 | NA | NA | Serum | 2883.76 | MALDI-TOF | Non-small cell lung cancer (NSCLC) | Upregulated in cancer vs normal | 22628229 |
| CancerPDF_ID3342 | NA | NA | Serum | 6047.64 | MALDI-TOF | Non-small cell lung cancer (NSCLC) | Upregulated in cancer vs normal | 22628229 |
| CancerPDF_ID3345 | NA | NA | Serum | 2932.99 | MALDI-TOF | Non-small cell lung cancer (NSCLC) | Upregulated in cancer vs normal | 22628229 |
| CancerPDF_ID3346 | NA | NA | Serum | 1887.15 | MALDI-TOF | Non-small cell lung cancer (NSCLC) | Upregulated in cancer vs normal | 22628229 |
| CancerPDF_ID3347 | NA | NA | Serum | 1897.93 | MALDI-TOF | Non-small cell lung cancer (NSCLC) | Upregulated in cancer vs normal | 22628229 |
| CancerPDF_ID3349 | NA | NA | Serum | 1741.38 | MALDI-TOF | Non-small cell lung cancer (NSCLC) | Upregulated in cancer vs normal | 22628229 |
| CancerPDF_ID3351 | NA | NA | Serum | 7468.37 | MALDI-TOF | Non-small cell lung cancer (NSCLC) | Upregulated in cancer vs normal | 22628229 |
| CancerPDF_ID3352 | NA | NA | Serum | 5292.77 | MALDI-TOF | Non-small cell lung cancer (NSCLC) | Upregulated in cancer vs normal | 22628229 |
| CancerPDF_ID3353 | NA | NA | Serum | 5079.68 | MALDI-TOF | Non-small cell lung cancer (NSCLC) | Upregulated in cancer vs normal | 22628229 |
| CancerPDF_ID3354 | NA | NA | Serum | 1350.83 | MALDI-TOF | Non-small cell lung cancer (NSCLC) | Upregulated in cancer vs normal | 22628229 |
| CancerPDF_ID3355 | NA | NA | Serum | 2554.64 | MALDI-TOF | Non-small cell lung cancer (NSCLC) | Upregulated in cancer vs normal | 22628229 |
| CancerPDF_ID3356 | NA | NA | Serum | 4529.7 | MALDI-TOF | Non-small cell lung cancer (NSCLC) | Upregulated in cancer vs normal | 22628229 |
| CancerPDF_ID3360 | NA | NA | Serum | 2669.09 | MALDI-TOF | Non-small cell lung cancer (NSCLC) | Upregulated in cancer vs normal | 22628229 |
| CancerPDF_ID3361 | NA | NA | Serum | 2878.89 | MALDI-TOF | Non-small cell lung cancer (NSCLC) | Upregulated in cancer vs normal | 22628229 |
| CancerPDF_ID3362 | NA | NA | Serum | 3208.49 | MALDI-TOF | Non-small cell lung cancer (NSCLC) | Upregulated in cancer vs normal | 22628229 |
| CancerPDF_ID3365 | NA | NA | Serum | 5264.02 | MALDI-TOF | Non-small cell lung cancer (NSCLC) | Upregulated in cancer vs normal | 22628229 |
| CancerPDF_ID3369 | NA | NA | Serum | 2953.31 | MALDI-TOF | Non-small cell lung cancer (NSCLC) | Upregulated in cancer vs normal | 22628229 |
| CancerPDF_ID3370 | NA | NA | Serum | 1450.55 | MALDI-TOF | Non-small cell lung cancer (NSCLC) | Upregulated in cancer vs normal | 22628229 |
| CancerPDF_ID3371 | NA | NA | Serum | 1779.31 | MALDI-TOF | Non-small cell lung cancer (NSCLC) | Upregulated in cancer vs normal | 22628229 |
| CancerPDF_ID3375 | NA | NA | Serum | 8562.86 | MALDI-TOF | Non-small cell lung cancer (NSCLC) | Upregulated in cancer vs normal | 22628229 |
| CancerPDF_ID3376 | NA | NA | Serum | 1082.44 | MALDI-TOF | Non-small cell lung cancer (NSCLC) | Upregulated in cancer vs normal | 22628229 |
| CancerPDF_ID3377 | NA | NA | Serum | 2769.86 | MALDI-TOF | Non-small cell lung cancer (NSCLC) | Upregulated in cancer vs normal | 22628229 |
| CancerPDF_ID3378 | NA | NA | Serum | 5753.12 | MALDI-TOF | Non-small cell lung cancer (NSCLC) | Upregulated in cancer vs normal | 22628229 |
| CancerPDF_ID3379 | NA | NA | Serum | 4281.54 | MALDI-TOF | Non-small cell lung cancer (NSCLC) | Upregulated in cancer vs normal | 22628229 |
| CancerPDF_ID3383 | NA | NA | Serum | 1563.43 | MALDI-TOF | Non-small cell lung cancer (NSCLC) | Upregulated in cancer vs normal | 22628229 |
| CancerPDF_ID3384 | NA | NA | Serum | 1331.12 | MALDI-TOF | Non-small cell lung cancer (NSCLC) | Upregulated in cancer vs normal | 22628229 |
| CancerPDF_ID3385 | NA | NA | Serum | 2545.83 | MALDI-TOF | Non-small cell lung cancer (NSCLC) | Upregulated in cancer vs normal | 22628229 |
| CancerPDF_ID3386 | NA | NA | Serum | 1866.42 | MALDI-TOF | Non-small cell lung cancer (NSCLC) | Upregulated in cancer vs normal | 22628229 |
| CancerPDF_ID3389 | NA | NA | Serum | 2281.08 | MALDI-TOF | Non-small cell lung cancer (NSCLC) | Upregulated in cancer vs normal | 22628229 |
| CancerPDF_ID3390 | NA | NA | Serum | 1563.11 | MALDI-TOF | Non-small cell lung cancer (NSCLC) | Upregulated in cancer vs normal | 22628229 |
| CancerPDF_ID3391 | NA | NA | Serum | 2281.08 | MALDI-TOF | Non-small cell lung cancer (NSCLC) | Upregulated in cancer vs normal | 22628229 |
| CancerPDF_ID3392 | NA | NA | Serum | 2682.65 | MALDI-TOF | Non-small cell lung cancer (NSCLC) | Upregulated in cancer vs normal | 22628229 |
| CancerPDF_ID3393 | NA | NA | Serum | 2900.91 | MALDI-TOF | Non-small cell lung cancer (NSCLC) | Upregulated in cancer vs normal | 22628229 |
| CancerPDF_ID3394 | NA | NA | Serum | 3279.09 | MALDI-TOF | Non-small cell lung cancer (NSCLC) | Upregulated in cancer vs normal | 22628229 |
| CancerPDF_ID3396 | NA | NA | Serum | 5247.81 | MALDI-TOF | Non-small cell lung cancer (NSCLC) | Upregulated in cancer vs normal | 22628229 |
| CancerPDF_ID3397 | NA | NA | Serum | 5336.3 | MALDI-TOF | Non-small cell lung cancer (NSCLC) | Upregulated in cancer vs normal | 22628229 |
| CancerPDF_ID3412 | DGESGRpGRpGERGLpGPpG | Collagen alpha-1(III) chain | Urine | NA | CE-MS-TOF | Bladder cancer | Upregulated in cancer vs normal | 21591268 |
| CancerPDF_ID3414 | AGPPGEAGKK PGEQGVPGDL | Collagen type a1 | Urine | NA | LC-MS | CRLM( Colorectal liver metastses) | Upregulated in cancer vs normal | 27186406 |
| CancerPDF_ID8612 | DEAGSEADHEGTHSTKRGHAKSRPV | Isoform 2 of fibrinogen (FGA) chain precursor | Serum | 2660.11 | MALDI-TOF | Breast cancer | Upregulated in cancer as compare to normal control with fold change of 1.5 | 26705257 |
| CancerPDF_ID8613 | SEMVVAGKLQ | Inter- trypsin inhibitor heavy chain H4 (ITIH4) precursor | Serum | 1061.09 | MALDI-TOF | Breast cancer | Upregulated in cancer as compare to normal control with fold change of 1.6 | 26705257 |
| CancerPDF_ID8614 | MNFRPGVLSSRQLGLPGPPDVPDHAAYHPF | Inter- trypsin inhibitor heavy chain H4 (ITIH4) fragment | Serum | 3273.69 | MALDI-TOF | Breast cancer | Upregulated in cancer as compare to normal control with fold change of 1.7 | 26705257 |
| CancerPDF_ID8615 | IAQDLEMYGINYFEIK | EZR (Ezrin fragment) | Serum | 1945.33 | MALDI-TOF | Breast cancer | Upregulated in cancer as compare to normal control with fold change of 1.8 | 26705257 |
| CancerPDF_ID8616 | HNLGHGHKHERDQGHGHQ | Isoform HMW of kininogen-1 (KNG1) precursor | Serum | 2082.04 | MALDI-TOF | Breast cancer | Upregulated in cancer as compare to normal control with fold change of 1.9 | 26705257 |
| CancerPDF_ID8617 | NVHSAGAAGSRMNFRPGVLSSRQLGLPGPPDVPDHAAYHPF | Inter- trypsin inhibitor heavy chain H4 (ITIH4) fragment | Serum | 4280.55 | MALDI-TOF | Breast cancer | Upregulated in cancer as compare to normal control with fold change of 1.10 | 26705257 |
| CancerPDF_ID8633 | GPPGPPGPPGLGG | Alpha-1 type I collagen | Urine | 1126.503 | MALDI-TOF | Cervical cancer | Upregulated in cancer vs normal | 24416269 |
| CancerPDF_ID8645 | NA | NA | Plasma | 2271.13 | MALDI-TOF | Cervical cancer | Upregulated in cancer as compare to normal control | 24416269 |
| CancerPDF_ID8646 | ALVETRTIVRFNRPFLMIIVPTDTQNIFFMSKVTNPKQA | Alpha 1 antichymotrypsin peptide ( C terminal fragment of protein AACT) | Cerbrospinal fluid | NA | MALDI-TOF | Glioblastoma (Malignant brain tumor) | Upregulated in cancer as compare to normal control | 19674866 |
| CancerPDF_ID8647 | SGPRRYTIAALLSPYSYSTTAVVTNPKE | Transthretin ( Cterminal fragment of protein TTHY) | Cerbrospinal fluid | NA | MALDI-TOF | Glioblastoma (Malignant brain tumor) | Upregulated in cancer as compare to normal control | 19674866 |
| CancerPDF_ID8648 | ANDESNEHSDVIDSQELSKVSREFHSHEFHSHEDMLVVDPKSKEEDKHLKFRISHELDSASSEVN | Osteopontin ( C terminal fragment of protein OPN) | Cerbrospinal fluid | NA | MALDI-TOF | Glioblastoma (Malignant brain tumor) | Upregulated in cancer as compare to normal control | 19674866 |
| CancerPDF_ID10277 | VRYTKKVPQVSTPTL | Serum albumin precursor | Urine | 1717.0035 | MALDI-TOF | Muscle-invasive bladder cancer | Upregulated with 2.26 fold change in muscle invasive bladder cancer vs non invasive bladder cancer and non cancer samples | 21805675 |
| CancerPDF_ID10339 | LVRYTKKVPQVSTPTL | Serum albumin precursor | Urine | 1830.0049 | MALDI-TOF | Muscle-invasive bladder cancer | Upregulated in cancer vs normal | 21805675 |
| CancerPDF_ID10497 | YSMRKMSMKIRPFFPQQ | Fibrinogen beta chain | Urine | 2175.0927 | MALDI-TOF | Muscle-invasive bladder cancer | Upregulated in cancer vs normal | 21805675 |
| CancerPDF_ID10557 | GTLSGIGTLDGFRHRHPDEAAF | Fibrinogen alpha chain | Urine | 2354.154 | MALDI-TOF | Muscle-invasive bladder cancer | Upregulated in cancer vs normal | 21805675 |
| CancerPDF_ID10575 | DAHKSEVAHRFKDLGEENFKA | Serum albumin precursor | Urine | 2428.2029 | MALDI-TOF | Muscle-invasive bladder cancer | Upregulated in cancer vs normal | 21805675 |
| CancerPDF_ID10584 | AAHLPAEFTPAVHASLDKFLASVS | Hemoglobin subunit alpha | Urine | 2479.2756 | MALDI-TOF | Muscle-invasive bladder cancer | Upregulated in cancer vs normal | 21805675 |
| CancerPDF_ID10639 | DAHKSEVAHRFKDLGEENFKALVL | Serum albumin precursor | Urine | 2753.4445 | MALDI-TOF | Muscle-invasive bladder cancer | Upregulated in cancer vs normal | 21805675 |
| CancerPDF_ID11033 | KEDIDTSSKGGCVQ | RNA-binding protein 6 | Serum | 1466.98 | MALDI-TOF | Clear cell renal carcinoma | "Upregulated in ccRCC, preoperative and post operative patients vs control" | 25368985 |
| CancerPDF_ID11034 | AILVDLEPGTMDSVR | tubulin beta chain | Serum | 1618.22 | MALDI-TOF | Clear cell renal carcinoma | "Upregulated in ccRCC, preoperative and post operative patients vs control" | 25368985 |
| CancerPDF_ID11035 | IHTGENPYECSECGKAFRYSSALVRHQRIHTGEKPLNGIGMSKSSLRVTTELN | zinc finger protein 3 | Serum | 5905.23 | MALDI-TOF | Clear cell renal carcinoma | "Upregulated in ccRCC, preoperative and post operative patients vs control" | 25368985 |
| CancerPDF_ID11041 | NA | NA | Serum | 5752.25 | MALDI-TOF | Clear cell renal carcinoma | "Upregulated in ccRCC, preoperative and post operative patients vs control" | 25368985 |
| CancerPDF_ID11042 | NA | NA | Serum | 5724.76 | MALDI-TOF | Clear cell renal carcinoma | "Upregulated in ccRCC, preoperative and post operative patients vs control" | 25368985 |
| CancerPDF_ID11043 | NA | NA | Serum | 5844.36 | MALDI-TOF | Clear cell renal carcinoma | "Upregulated in ccRCC, preoperative and post operative patients vs control" | 25368985 |
| CancerPDF_ID11044 | NA | NA | Serum | 5739.69 | MALDI-TOF | Clear cell renal carcinoma | "Upregulated in ccRCC, preoperative and post operative patients vs control" | 25368985 |
| CancerPDF_ID11045 | NA | NA | Serum | 5818.83 | MALDI-TOF | Clear cell renal carcinoma | "Upregulated in ccRCC, preoperative and post operative patients vs control" | 25368985 |
| CancerPDF_ID11046 | NA | NA | Serum | 4091.86 | MALDI-TOF | Clear cell renal carcinoma | "Upregulated in ccRCC, preoperative and post operative patients vs control" | 25368985 |
| CancerPDF_ID11047 | NA | NA | Serum | 1714.57 | MALDI-TOF | Clear cell renal carcinoma | "Upregulated in ccRCC, preoperative and post operative patients vs control" | 25368985 |
| CancerPDF_ID11051 | NRIPESGGDNSVFDIFELTGAARKGSGR | Thrombospondin-1 | Serum | 2950.6 | MALDI-TOF | Esophageal squamous cell carcinoma (ESCC) | Upregulated in patients vs normal with mean intensity 84.95 in control and 666.08 in cancer | 26993605 |
| CancerPDF_ID11052 | SSSYSKQFTSSTSYNRGDSTFESKSYKMADEAGSEADHEGTHSTKRGHAKSRPV | Fibrinogen alpha chain | Serum | 5900 | MALDI-TOF | Esophageal squamous cell carcinoma (ESCC) | Upregulated in patients vs normal with mean intensity 100.55 in normal and 831.12 in cancer | 26993605 |
| CancerPDF_ID11054 | SSYSKQFTSSTSYNRGDST | Fibrinogen alpha chain | Serum | 2102.7 | MALDI-TOF | Esophageal squamous cell carcinoma (ESCC) | Upregulated in ESCC patients vs control with mean intensity in cancer as 532.28 and mean intensity in control as 266.24 | 26993605 |
| CancerPDF_ID11056 | SYKMADEAGSEADHEGTHSTKRGHAKSRPV | Fibrinogen alpha chain | Serum | 3239.9 | MALDI-TOF | Esophageal squamous cell carcinoma (ESCC) | Upregulated in ESCC patients vs control with mean intensity in cancer as 831.12 and mean intensity in control as 100.55 | 26993605 |
| CancerPDF_ID11058 | NVHSGSTFFKYYLQGAKIPKPEAS | ITIH4 | Serum | 2669.1 | MALDI-TOF | Esophageal squamous cell carcinoma (ESCC) | Upregulated in ESCC patients vs control with mean intensity in cancer 417.72 and mean intensity in normal 190.00 | 26993605 |
| CancerPDF_ID11059 | QLGLPGPPDVPDHAAYHPF | ITIH4 | Serum | 2026.8 | MALDI-TOF | Esophageal squamous cell carcinoma (ESCC) | "Upregulated in ESCC patients vs control with mean intensity in cancer as 2,730.99 and mean intensity in normal 1,290.54" | 26993605 |
| CancerPDF_ID11060 | CSRDNTLKVIDLR | isoform CRA_b | Serum | 1532.1 | MALDI-TOF | Esophageal squamous cell carcinoma (ESCC) | "Upregulated in ESCC patients vs control with mean intensity in cancer as 1,022.00 and mean intensity in normal as 527.84" | 26993605 |
| CancerPDF_ID11061 | NA | NA | Serum | 5924.6 | MALDI-TOF | Esophageal squamous cell carcinoma (ESCC) | Upregulated in ESCC patients vs control with mean intensity in cancer as 425.63 and mean intensity in normal as 50.61 | 26993605 |
| CancerPDF_ID11062 | NA | NA | Serum | 5910 | MALDI-TOF | Esophageal squamous cell carcinoma (ESCC) | Upregulated in ESCC patients vs control with mean intensity in cancer as 739.57 and mean intensity in normal as 87.40 | 26993605 |
| CancerPDF_ID11063 | NA | NA | Serum | 5882.1 | MALDI-TOF | Esophageal squamous cell carcinoma (ESCC) | Upregulated in ESCC patients vs control with mean intensity in cancer as 681.97 and mean intensity in normal as 114.65 | 26993605 |
| CancerPDF_ID11064 | NA | NA | Serum | 4209.6 | MALDI-TOF | Esophageal squamous cell carcinoma (ESCC) | Upregulated in ESCC patients vs control with mean intensity in cancer as 1772.59 and mean intensity in normal as 696.17 | 26993605 |
| CancerPDF_ID11065 | NA | NA | Serum | 4199.6 | MALDI-TOF | Esophageal squamous cell carcinoma (ESCC) | Upregulated in ESCC patients vs control with mean intensity in cancer as 1767.14 and mean intensity in normal as 867.09 | 26993605 |
| CancerPDF_ID11066 | NA | NA | Serum | 4225.6 | MALDI-TOF | Esophageal squamous cell carcinoma (ESCC) | Upregulated in ESCC patients vs control with mean intensity in cancer as 526.85 and mean intensity in normal as224.98 | 26993605 |
| CancerPDF_ID11067 | NA | NA | Serum | 3883.6 | MALDI-TOF | Esophageal squamous cell carcinoma (ESCC) | Upregulated in ESCC patients vs control | 26993605 |
| CancerPDF_ID11068 | NA | NA | Serum | 3249.2 | MALDI-TOF | Esophageal squamous cell carcinoma (ESCC) | Upregulated in ESCC patients vs control | 26993605 |
| CancerPDF_ID11069 | NA | NA | Serum | 4086.1 | MALDI-TOF | Esophageal squamous cell carcinoma (ESCC) | Upregulated in ESCC patients vs control | 26993605 |
| CancerPDF_ID11073 | SSSYSKQFTSST SYNRGDSTFESKSYKMADEAGSEADHEGTH STKRGHAKSR | Fibrinogen alpha chain | Blood | 5910 | MALDI-TOF | Gastric cancer | Upregulated in gastric patients vs healthy with 45.5±13.1 intesity in cancer patients and 9.2±4.7 intensity in normal pateints | 26662807 |
| CancerPDF_ID11076 | NA | A1AG1_HUMAN | Urine | 1755.759 | MALDI-TOF | Clear cell renal carcinoma | "Upregulated with increse in tumor mass,primary tumor stage" | 26482227 |
| CancerPDF_ID11077 | NA | A1AG2_HUMAN | Urine | 1755.759 | MALDI-TOF | Clear cell renal carcinoma | "Upregulated with increse in tumor mass,primary tumor stage" | 26482227 |
| CancerPDF_ID11086 | NA | FIBA_HUMAN | Urine | 2660.82 | MALDI-TOF | Clear cell renal carcinoma | Upregulated with increse in tumor mass | 26482227 |
| CancerPDF_ID11098 | NA | GP162_HUMAN | Urine | 2192.1 | MALDI-TOF | Clear cell renal carcinoma | Upregulated in pT1b compared to pT1a patients | 26482227 |
| CancerPDF_ID11099 | NA | KPB1_HUMAN | Urine | 2192.1 | MALDI-TOF | Clear cell renal carcinoma | Upregulated in pT1b compared to pT1a patients | 26482227 |
| CancerPDF_ID11100 | NA | HBA_HUMAN | Urine | 2790.7 | MALDI-TOF | Clear cell renal carcinoma | Upregulated in pT1b compared to pT1a patients | 26482227 |
| CancerPDF_ID11101 | NA | SAFB2_HUMAN | Urine | 4355.1 | MALDI-TOF | Clear cell renal carcinoma | Upregulated in pT1b compared to pT1a patients | 26482227 |
| CancerPDF_ID11102 | NA | CC168_HUMAN | Urine | 4626.9 | MALDI-TOF | Clear cell renal carcinoma | Upregulated in pT1b compared to pT1a patients | 26482227 |
| CancerPDF_ID11105 | NA | NA | Urine | 4366.9 | MALDI-TOF | Clear cell renal carcinoma | Upregulated in pT1b compared to pT1a patients | 26482227 |
| CancerPDF_ID11106 | NA | NA | Urine | 4439.1 | MALDI-TOF | Clear cell renal carcinoma | Upregulated in pT1b compared to pT1a patients | 26482227 |
| CancerPDF_ID11107 | NA | NA | Urine | 4751.5 | MALDI-TOF | Clear cell renal carcinoma | Upregulated in pT1b compared to pT1a patients | 26482227 |
| CancerPDF_ID11108 | NA | NA | Urine | 5514.2 | MALDI-TOF | Clear cell renal carcinoma | Upregulated in pT1b compared to pT1a patients | 26482227 |
| CancerPDF_ID11109 | NA | NA | Urine | 6237.8 | MALDI-TOF | Clear cell renal carcinoma | Upregulated in pT1b compared to pT1a patients | 26482227 |
| CancerPDF_ID11110 | NA | NA | Urine | 1023.9 | MALDI-TOF | Clear cell renal carcinoma | Upregulated in grade vs normal | 26482227 |
| CancerPDF_ID11111 | NA | NA | Urine | 1194.2 | MALDI-TOF | Clear cell renal carcinoma | Upregulated in grade vs normal | 26482227 |
| CancerPDF_ID11112 | NA | NA | Urine | 1825.6 | MALDI-TOF | Clear cell renal carcinoma | Upregulated in grade vs normal | 26482227 |
| CancerPDF_ID11114 | NA | NA | Urine | 3571.1 | MALDI-TOF | Clear cell renal carcinoma | Upregulated in grade vs normal | 26482227 |
| CancerPDF_ID11120 | NA | NA | Urine | 5231.5 | MALDI-TOF | Clear cell renal carcinoma | Upregulated in grade vs normal | 26482227 |
| CancerPDF_ID11121 | NA | NA | Urine | 1755.8 | MALDI-TOF | Clear cell renal carcinoma | Upregulated in ccRCC vs normal according to primary tumor Stage | 26482227 |
| CancerPDF_ID11125 | NA | NA | Urine | 2660.8 | MALDI-TOF | Clear cell renal carcinoma | Upregulated in ccRCC vs normal according to primary tumor Stage | 26482227 |
| CancerPDF_ID11130 | NA | NA | Urine | 4962.8 | MALDI-TOF | Clear cell renal carcinoma | Upregulated in ccRCC vs normal according to primary tumor Stage | 26482227 |
| CancerPDF_ID11131 | NA | NA | Urine | 5231.5 | MALDI-TOF | Clear cell renal carcinoma | Upregulated in ccRCC vs normal according to primary tumor Stage | 26482227 |
| CancerPDF_ID12676 | QGLLPVLESFKVSFLSALEEYTKKLNTQ | Apolipoprotein A-I | Serum | NA | LC-MS | Renal cell carcinaoma | Upregulated in cancer v/s Normal | 25168216 |
| CancerPDF_ID12677 | DDPDAPLQPVTPLQLFEGRRN | Complement C4 | Serum | NA | LC-MS | Renal cell carcinaoma | Upregulated in cancer v/s Normal | 25168216 |
| CancerPDF_ID12678 | DSGEGDFLAEGGGVR | Fibrinogen alpha chain | Serum | NA | LC-MS | Renal cell carcinaoma | Upregulated in cancer v/s Normal | 25168216 |
| CancerPDF_ID12679 | LPILKIIPI | Dynein heavy chain | Serum | NA | LC-MS | Renal cell carcinaoma | Upregulated in cancer v/s Normal | 25168216 |
| CancerPDF_ID12680 | SLAELGGHLDQQVEEF | Apolipoprotein A-IV | Serum | NA | LC-MS | Renal cell carcinaoma | Upregulated in cancer v/s Normal | 25168216 |
| CancerPDF_ID12682 | APKPHAFVGSVK | Putative Polycombgroup Protein ASXL1 | Serum | NA | LC-MS | Renal cell carcinaoma | Upregulated in cancer v/s Normal | 25168216 |
| CancerPDF_ID12683 | IILILAILR | Major facilitator superfamily domain-containing protein 8 | Serum | NA | LC-MS | Renal cell carcinaoma | Upregulated in cancer v/s Normal | 25168216 |
| CancerPDF_ID12684 | DFWRKMYLREP | Zinc finger protein 233 | Serum | NA | LC-MS | Renal cell carcinaoma | Upregulated in cancer v/s Normal | 25168216 |
| CancerPDF_ID12685 | GEGDFLAEGGGVR | Fibrinogen alpha chain | Serum | NA | LC-MS | Renal cell carcinaoma | Upregulated in cancer v/s Normal | 25168216 |
| CancerPDF_ID12686 | EGDFLAEGGGVR | Fibrinogen alpha chain | Serum | NA | LC-MS | Renal cell carcinaoma | Upregulated in cancer v/s Normal | 25168216 |
| CancerPDF_ID12687 | SGEGDFLAEGGGVR | Fibrinogen alpha chain | Serum | NA | LC-MS | Renal cell carcinaoma | Upregulated in cancer v/s Normal | 25168216 |
| CancerPDF_ID12691 | RALAFR | NA | Serum | NA | LC-MS | Renal cell carcinaoma | Upregulated in cancer v/s Normal | 25168216 |
| CancerPDF_ID12692 | NA | NA | Serum | NA | LC-MS | Renal cell carcinaoma | Upregulated in cancer v/s Normal | 25168216 |
| CancerPDF_ID12693 | VSFLSALEEYTKKLNTQ | Apolipoprotein A-I | Serum | 1970.984 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.57 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.88, Upregulated in BC vs healthy with 0.925 fold change" | 27058005 |
| CancerPDF_ID12694 | HTFMGVVSLGSPSGEVSHPRKT | Alpha-2-HS-glycoprotein | Serum | 2326.204 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.58 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.25, Upregulated in BC vs healthy with 1.217 fold change" | 27058005 |
| CancerPDF_ID12695 | HRIHWE | Complement C3 | Serum | 877.0667 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 1.19 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.25, Upregulated in BC vs healthy with 1.065 fold change" | 27058005 |
| CancerPDF_ID12696 | IHWESASLL | Complement C3 | Serum | 1055.082 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 1.21 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.27, Upregulated in BC vs healthy with 1.126 fold change" | 27058005 |
| CancerPDF_ID12697 | SSKITHRIH | Complement C3 | Serum | 1078.125 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 1.03 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.19, Upregulated in BC vs healthy with 1.006 fold change" | 27058005 |
| CancerPDF_ID12698 | SVQLTEKRMD | Complement C3 | Serum | 1206.7 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 1.02 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.13, Upregulated in BC vs healthy with 1.024 fold change" | 27058005 |
| CancerPDF_ID12699 | RIHWESASLL | Complement C3 | Serum | 1211.694 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 1.17 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.22, Upregulated in BC vs healthy with 1.157 fold change" | 27058005 |
| CancerPDF_ID12700 | HRIHWESASLL | Complement C3 | Serum | 1348.755 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 1.59 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.13, Upregulated in BC vs healthy with 1.042 fold change" | 27058005 |
| CancerPDF_ID12701 | THRIHWESASLL | Complement C3 | Serum | 1449.804 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 1.52 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.25, Upregulated in BC vs healthy with 1.134 fold change" | 27058005 |
| CancerPDF_ID12702 | SKITHRIHWESAS | Complement C3 | Serum | 1551.893 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 1.18 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.17, Upregulated in BC vs healthy with 1.156 fold change" | 27058005 |
| CancerPDF_ID12703 | ITHRIHWESASLL | Complement C3 | Serum | 1562.888 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 1.30 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.22, Upregulated in BC vs healthy with 1.134 fold change" | 27058005 |
| CancerPDF_ID12704 | SVQLTEKRMDKVGK | Complement C3 | Serum | 1634.944 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.95 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.04, Upregulated in BC vs healthy with 1.049 fold change" | 27058005 |
| CancerPDF_ID12705 | KITHRIHWESASLL | Complement C3 | Serum | 1690.987 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 2.19 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.36, Upregulated in BC vs healthy with 1.341 fold change" | 27058005 |
| CancerPDF_ID12706 | SKITHRIHWESASLL | Complement C3 | Serum | 1778.018 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 2.10 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.37, Upregulated in BC vs healthy with 1.343 fold change" | 27058005 |
| CancerPDF_ID12707 | KITHRIHWESASLLR | Complement C3 | Serum | 1847.095 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 1.26 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.30, Upregulated in BC vs healthy with 1.623 fold change" | 27058005 |
| CancerPDF_ID12708 | SSKITHRIHWESASLL | Complement C3 | Serum | 1865.05 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 2.06 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.35, Upregulated in BC vs healthy with 1.344 fold change" | 27058005 |
| CancerPDF_ID12709 | SSKITHRIHWESASLLR | Complement C3 | Serum | 2021.146 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 1.02 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.19, Upregulated in BC vs healthy with 1.844 fold change" | 27058005 |
| CancerPDF_ID12710 | GFKSHALQLNNRQI | Complement C4 | Serum | 1625.946 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.68 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.78, Upregulated in BC vs healthy with 0.763 fold change" | 27058005 |
| CancerPDF_ID12711 | NGFKSHALQLNNRQ | Complement C4 | Serum | 1626.912 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.56 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.80, Upregulated in BC vs healthy with 0.754 fold change" | 27058005 |
| CancerPDF_ID12712 | NGFKSHALQLNNRQI | Complement C4 | Serum | 1739.971 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.76 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.83, Upregulated in BC vs healthy with 0.796 fold change" | 27058005 |
| CancerPDF_ID12713 | GFKSHALQLNNRQIR | Complement C4 | Serum | 1782.012 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 1.73 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.16, Upregulated in BC vs healthy with 1.092 fold change" | 27058005 |
| CancerPDF_ID12714 | NGFKSHALQLNNRQIR | Complement C4 | Serum | 1896.068 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.45 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.00, Upregulated in BC vs healthy with 0.968 fold change" | 27058005 |
| CancerPDF_ID12715 | HFFFPK | Clusterin | Serum | 822.485 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.31 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.10, Upregulated in BC vs healthy with 1.029 fold change" | 27058005 |
| CancerPDF_ID12716 | FPKSRIV | Clusterin | Serum | 846.533 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.50 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.21, Upregulated in BC vs healthy with 1.139 fold change" | 27058005 |
| CancerPDF_ID12717 | HFFFPKSRIV | Clusterin | Serum | 1277.758 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.39 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.17, Upregulated in BC vs healthy with 1.117 fold change" | 27058005 |
| CancerPDF_ID12718 | RPHFFFPKSRIV | Clusterin | Serum | 1530.912 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.26 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.16, Upregulated in BC vs healthy with 1.106 fold change" | 27058005 |
| CancerPDF_ID12719 | AVPPNNSNAAEDDLPTVELQGVVPR | Coagulation factor XIII A chain | Serum | 2602.306 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.47 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.04, Upregulated in BC vs healthy with 1.073 fold change" | 27058005 |
| CancerPDF_ID12720 | FLAEGGGVR | Fibrinogen alpha chain | Serum | 905.065 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 1.28 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.35, Upregulated in BC vs healthy with 1.203 fold change" | 27058005 |
| CancerPDF_ID12721 | SSSYSKQFTSSTS | Fibrinogen alpha chain | Serum | 1396.795 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.57 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.01, Upregulated in BC vs healthy with 0.963 fold change" | 27058005 |
| CancerPDF_ID12722 | NRGDSTFESKSYKM | Fibrinogen alpha chain | Serum | 1665.957 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.65 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.06, Upregulated in BC vs healthy with 1.083 fold change" | 27058005 |
| CancerPDF_ID12723 | SSSYSKQFTSSTSYNRGDSTFES | Fibrinogen alpha chain | Serum | 2553.201 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.60 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.85, Upregulated in BC vs healthy with 0.992 fold change" | 27058005 |
| CancerPDF_ID12724 | DEAGSEADHEGTHSTKRGHAKSRPV | Fibrinogen alpha chain | Serum | 2659.323 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.73 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.88, Upregulated in BC vs healthy with 1.033 fold change" | 27058005 |
| CancerPDF_ID12725 | SSSYSKQFTSSTSYNRGDSTFESKS | Fibrinogen alpha chain | Serum | 2768.32 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 1.35 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.18, Upregulated in BC vs healthy with 1.074 fold change" | 27058005 |
| CancerPDF_ID12726 | SSYSKQFTSSTSYNRGDSTFESKSY | Fibrinogen alpha chain | Serum | 2931.376 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.79 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.00, Upregulated in BC vs healthy with 1.128 fold change" | 27058005 |
| CancerPDF_ID12727 | KMADEAGSEADHEGTHSTKRGHAKSRPV | Fibrinogen alpha chain | Serum | 3005.608 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 1.73 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 2.39, Upregulated in BC vs healthy with 2.324 fold change" | 27058005 |
| CancerPDF_ID12728 | SSSYSKQFTSSTSYNRGDSTFESKSYKM | Fibrinogen alpha chain | Serum | 3206.443 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 1.44 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.05, Upregulated in BC vs healthy with 0.958 fold change" | 27058005 |
| CancerPDF_ID12729 | SSSYSKQFTSSTSYNRGDSTFESKSYKMA | Fibrinogen alpha chain | Serum | 3277.592 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 1.43 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.11, Upregulated in BC vs healthy with 0.942 fold change" | 27058005 |
| CancerPDF_ID12730 | QAGAAGSRMNFRPGVLS | Inter-alpha-trypsin inhibitor heavy chain H5 | Serum | 1717.941 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.91 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.93, Upregulated in BC vs healthy with 1.276 fold change" | 27058005 |
| CancerPDF_ID12731 | QAGAAGSRMNFRPGVLSS | Inter-alpha-trypsin inhibitor heavy chain H5 | Serum | 1804.918 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.93 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.04, Upregulated in BC vs healthy with 1.080 fold change" | 27058005 |
| CancerPDF_ID12732 | YLQGAKIPKPEASFSPR | Inter-alpha-trypsin inhibitor heavy chain H5 | Serum | 1889.031 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 1.14 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.08, Upregulated in BC vs healthy with 1.244 fold change" | 27058005 |
| CancerPDF_ID12733 | YYLQGAKIPKPEASFSPR | Inter-alpha-trypsin inhibitor heavy chain H5 | Serum | 2051.125 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.80 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.02, Upregulated in BC vs healthy with 1.047 fold change" | 27058005 |
| CancerPDF_ID12734 | SRQLGLPGPPDVPDHAAYHPF | Inter-alpha-trypsin inhibitor heavy chain H5 | Serum | 2271.203 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.99 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.93, Upregulated in BC vs healthy with 1.221 fold change" | 27058005 |
| CancerPDF_ID12735 | NVHSGSTFFKYYLQGAKIPKPEA | Inter-alpha-trypsin inhibitor heavy chain H5 | Serum | 2582.393 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.38 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.62, Upregulated in BC vs healthy with 0.975 fold change" | 27058005 |
| CancerPDF_ID12736 | GVLSSRQLGLPGPPDVPDHAAYHPF | Inter-alpha-trypsin inhibitor heavy chain H5 | Serum | 2627.365 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.51 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.86, Upregulated in BC vs healthy with 0.931 fold change" | 27058005 |
| CancerPDF_ID12737 | PGVLSSRQLGLPGPPDVPDHAAYHPF | Inter-alpha-trypsin inhibitor heavy chain H5 | Serum | 2724.46 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.22 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.72, Upregulated in BC vs healthy with 1.080 fold change" | 27058005 |
| CancerPDF_ID12738 | NVHSGSTFFKYYLQGAKIPKPEASFSPR | Inter-alpha-trypsin inhibitor heavy chain H5 | Serum | 3156.679 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.52 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.11, Upregulated in BC vs healthy with 1.158 fold change" | 27058005 |
| CancerPDF_ID12739 | MNFRPGVLSSRQLGLPGPPDVPDHAAYHPF | Inter-alpha-trypsin inhibitor heavy chain H5 | Serum | 3272.752 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.42 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.89, Upregulated in BC vs healthy with 1.036 fold change" | 27058005 |
| CancerPDF_ID12740 | MNFRPGVLSSRQLGLPGPPDVPDHAAYHPF | Inter-alpha-trypsin inhibitor heavy chain H5 | Serum | 3288.759 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.34 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.85, Upregulated in BC vs healthy with 1.126 fold change" | 27058005 |
| CancerPDF_ID12741 | QAGAAGSRMNFRPGVLSSRQLGLPGPPDVPDHAAYHPF | Inter-alpha-trypsin inhibitor heavy chain H5 | Serum | 3969.989 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.57 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.82, Upregulated in BC vs healthy with 1.170 fold change" | 27058005 |
| CancerPDF_ID12742 | RPPGFSPF | Kininogen-1 | Serum | 904.5017 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.29 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.40, Upregulated in BC vs healthy with 0.902 fold change" | 27058005 |
| CancerPDF_ID12743 | RPPGFSPFR | Kininogen-1 | Serum | 1060.627 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.79 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.82, Upregulated in BC vs healthy with 0.818 fold change" | 27058005 |
| CancerPDF_ID12744 | GHKHERDQGHGHQ | Kininogen-1 | Serum | 1522.838 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.81 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.88, Upregulated in BC vs healthy with 1.118 fold change" | 27058005 |
| CancerPDF_ID12745 | HGHKHERDQGHGHQ | Kininogen-1 | Serum | 1659.808 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.47 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.65, Upregulated in BC vs healthy with 1.231 fold change" | 27058005 |
| CancerPDF_ID12746 | GHGHKHERDQGHGHQ | Kininogen-1 | Serum | 1716.955 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 1.25 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.11, Upregulated in BC vs healthy with 1.154 fold change" | 27058005 |
| CancerPDF_ID12747 | NLGHGHKHERDQGHGHQ | Kininogen-1 | Serum | 1943.95 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.45 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.43, Upregulated in BC vs healthy with 1.386 fold change" | 27058005 |
| CancerPDF_ID12748 | HGLGHGHEQQHGLGHGHKF | Kininogen-1 | Serum | 2070.011 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.25 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.62, Upregulated in BC vs healthy with 1.201 fold change" | 27058005 |
| CancerPDF_ID12749 | HNLGHGHKHERDQGHGHQ | Kininogen-1 | Serum | 2081.006 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.43 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.71, Upregulated in BC vs healthy with 1.565 fold change" | 27058005 |
| CancerPDF_ID12750 | GHGLGHGHEQQHGLGHGHKF | Kininogen-1 | Serum | 2127.055 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.10 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.48, Upregulated in BC vs healthy with 1.279 fold change" | 27058005 |
| CancerPDF_ID12751 | KHNLGHGHKHERDQGHGHQ | Kininogen-1 | Serum | 2209.11 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.31 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.29, Upregulated in BC vs healthy with 1.499 fold change" | 27058005 |
| CancerPDF_ID12752 | KHNLGHGHKHERDQGHGHQR | Kininogen-1 | Serum | 2365.208 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 1.62 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.87, Upregulated in BC vs healthy with 1.340 fold change" | 27058005 |
| CancerPDF_ID12753 | GGPGGAGVARGGAGGGP | Neurogranin | Serum | 1251.732 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 1.16 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.07, Upregulated in BC vs healthy with 1.103 fold change" | 27058005 |
| CancerPDF_ID12754 | TPHPRPAPQSKPLASSGVPE | RIMS-binding protein-2 | Serum | 2053.134 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.77 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.99, Upregulated in BC vs healthy with 1.495 fold change" | 27058005 |
| CancerPDF_ID12755 | DFLAEGGGVR | "FGA, Isoform 2 of Fibrinogen alpha chain" | Serum | 1025.5 | MALDI-TOF | Cervical cancer | Upregulated in Cervical squamous cell carcinoma vs healthy | 26282206 |
| CancerPDF_ID12756 | HRHPDEAAFFDTASTGK | "FGA, Isoform 2 of Fibrinogen alpha chain" | Serum | 1889.4 | MALDI-TOF | Cervical cancer | Upregulated in Cervical squamous cell carcinoma vs healthy | 26282206 |
| CancerPDF_ID12757 | NGFKSHALQLNNRQIR | Complement C4eB-like Isoform 1 | Serum | 1898.9 | MALDI-TOF | Cervical cancer | Upregulated in Cervical squamous cell carcinoma vs healthy | 26282206 |
| CancerPDF_ID12758 | NA | NA | Serum | 2107.5 | MALDI-TOF | Cervical cancer | Upregulated in Cervical squamous cell carcinoma vs healthy | 26282206 |
| CancerPDF_ID12764 | NA | NA | Serum | 3885.5 | MALDI-TOF | Cervical cancer | Upregulated in Cervical squamous cell carcinoma vs healthy | 26282206 |
| CancerPDF_ID12765 | NA | NA | Serum | 4055.4 | MALDI-TOF | Cervical cancer | Upregulated in Cervical squamous cell carcinoma vs healthy | 26282206 |
| CancerPDF_ID12766 | NA | NA | Serum | 4470.9 | MALDI-TOF | Cervical cancer | Upregulated in Cervical squamous cell carcinoma vs healthy | 26282206 |
| CancerPDF_ID12767 | NA | NA | Serum | 5893.8 | MALDI-TOF | Cervical cancer | Upregulated in Cervical squamous cell carcinoma vs healthy | 26282206 |
| CancerPDF_ID12768 | NA | NA | Serum | 7773 | MALDI-TOF | Cervical cancer | Upregulated in Cervical squamous cell carcinoma vs healthy | 26282206 |
| CancerPDF_ID12780 | NA | NA | Serum | 1082.55 | MALDI-TOF | Hepatocellular carcinoma | Upregulated in cancer vs Healthy | 25910294 |
| CancerPDF_ID12784 | NA | NA | Serum | 2354.46 | MALDI-TOF | Hepatocellular carcinoma | Upregulated in cancer vs Healthy | 25910294 |
| CancerPDF_ID12845 | NA | NA | Serum | NA | MALDI-TOF | Acute myeloid leukemia (AML) | Upregulated in AML vs healthy | 23915341 |
| CancerPDF_ID12847 | NA | NA | Serum | NA | MALDI-TOF | Acute myeloid leukemia (AML) | Upregulated in AML vs healthy | 23915341 |
| CancerPDF_ID12855 | NA | NA | Serum | NA | MALDI-TOF | Acute myeloid leukemia (AML) | Upregulated in AML vs healthy | 23915341 |
| CancerPDF_ID12856 | NA | NA | Serum | NA | MALDI-TOF | Acute myeloid leukemia (AML) | Upregulated in AML vs healthy | 23915341 |
| CancerPDF_ID12866 | NA | NA | Serum | NA | MALDI-TOF | Acute myeloid leukemia (AML) | Upregulated in AML vs healthy | 23915341 |
| CancerPDF_ID12875 | NA | NA | Serum | NA | MALDI-TOF | Acute myeloid leukemia (AML) | Upregulated in AML vs healthy | 23915341 |
| CancerPDF_ID12877 | NA | NA | Serum | NA | MALDI-TOF | Acute myeloid leukemia (AML) | Upregulated in AML vs healthy | 23915341 |
| CancerPDF_ID12882 | NA | NA | Serum | NA | MALDI-TOF | Acute myeloid leukemia (AML) | Upregulated in AML vs healthy | 23915341 |
| CancerPDF_ID12884 | NA | NA | Serum | NA | MALDI-TOF | Acute myeloid leukemia (AML) | Upregulated in AML vs healthy | 23915341 |
| CancerPDF_ID12885 | NA | NA | Serum | NA | MALDI-TOF | Acute myeloid leukemia (AML) | Upregulated in AML vs healthy | 23915341 |
| CancerPDF_ID12888 | NA | NA | Serum | NA | MALDI-TOF | Acute myeloid leukemia (AML) | Upregulated in AML vs healthy | 23915341 |
| CancerPDF_ID12890 | NA | NA | Serum | NA | MALDI-TOF | Acute myeloid leukemia (AML) | Upregulated in AML vs healthy | 23915341 |
| CancerPDF_ID12891 | NA | NA | Serum | NA | MALDI-TOF | Breast cancer | Upregulated in breast cancer patients vs healthy | 22521044 |
| CancerPDF_ID12892 | NA | NA | Serum | NA | MALDI-TOF | Breast cancer | Upregulated in breast cancer patients vs healthy | 22521044 |
| CancerPDF_ID12893 | NA | NA | Serum | NA | MALDI-TOF | Breast cancer | Upregulated in breast cancer patients vs healthy | 22521044 |
| CancerPDF_ID12894 | NA | NA | Serum | NA | MALDI-TOF | Breast cancer | Upregulated in breast cancer patients vs healthy | 22521044 |
| CancerPDF_ID12897 | NA | NA | Serum | NA | MALDI-TOF | Breast cancer | Upregulated in breast cancer patients vs healthy | 22521044 |
| CancerPDF_ID12898 | NA | NA | Serum | NA | MALDI-TOF | Breast cancer | Upregulated in breast cancer patients vs healthy | 22521044 |
| CancerPDF_ID12899 | NA | NA | Serum | NA | MALDI-TOF | Breast cancer | Upregulated in breast cancer patients vs healthy | 22521044 |
| CancerPDF_ID12902 | NA | NA | Serum | NA | MALDI-TOF | Breast cancer | Upregulated in breast cancer patients vs healthy | 22521044 |
| CancerPDF_ID12903 | NA | NA | Serum | NA | MALDI-TOF | Breast cancer | Upregulated in breast cancer patients vs healthy | 22521044 |
| CancerPDF_ID12909 | NA | NA | Serum | NA | MALDI-TOF | Breast cancer | Upregulated in breast cancer patients vs healthy | 22521044 |
| CancerPDF_ID12910 | NA | NA | Serum | NA | MALDI-TOF | Breast cancer | Upregulated in breast cancer patients vs healthy | 22521044 |
| CancerPDF_ID12911 | NA | NA | Serum | NA | MALDI-TOF | Breast cancer | Upregulated in breast cancer patients vs healthy | 22521044 |
| CancerPDF_ID12912 | NA | NA | Serum | NA | MALDI-TOF | Breast cancer | Upregulated in breast cancer patients vs healthy | 22521044 |
| CancerPDF_ID12913 | NA | NA | Serum | NA | MALDI-TOF | Breast cancer | Upregulated in breast cancer patients vs healthy | 22521044 |
| CancerPDF_ID12914 | NA | NA | Serum | NA | MALDI-TOF | Breast cancer | Upregulated in breast cancer patients vs healthy | 22521044 |
| CancerPDF_ID12915 | NA | NA | Serum | "3,316.09" | MALDI-TOF | Gastric cancer | Upregulated in gastric cancer vs healthy | 21739109 |
| CancerPDF_ID12919 | NA | NA | Serum | "6,622.59" | MALDI-TOF | Gastric cancer | Upregulated in Gastric cancer vs healthy | 21739109 |
| CancerPDF_ID12923 | NA | NA | Serum | "3,217.15" | MALDI-TOF | Gastric cancer | Upregulated in Gastric cancer vs healthy | 21739109 |
| CancerPDF_ID14044 | NA | NA | Serum | 1081.19 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14047 | NA | NA | Serum | 1119.63 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14048 | NA | NA | Serum | 1128.08 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14059 | NA | NA | Serum | 1302.12 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14060 | NA | NA | Serum | 1309.55 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14061 | NA | NA | Serum | 1310.35 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14063 | NA | NA | Serum | 1346.96 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14072 | NA | NA | Serum | 1469.88 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14074 | NA | NA | Serum | 1491.34 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14077 | NA | NA | Serum | 1513.8 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14099 | NA | NA | Serum | 1710.37 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14100 | NA | NA | Serum | 1720.96 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14101 | NA | NA | Serum | 1738.52 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14102 | NA | NA | Serum | 1751.72 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14103 | NA | NA | Serum | 1759.67 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14104 | NA | NA | Serum | 1775.86 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14105 | NA | NA | Serum | 1791.07 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14106 | NA | NA | Serum | 1797.47 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14107 | NA | NA | Serum | 1805.94 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14108 | NA | NA | Serum | 1812.88 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14109 | NA | NA | Serum | 1831.4 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14110 | NA | NA | Serum | 1837.36 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14111 | NA | NA | Serum | 1846.16 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14112 | NA | NA | Serum | 1883.63 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14113 | NA | NA | Serum | 1899.32 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14114 | NA | NA | Serum | 1905.69 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14115 | NA | NA | Serum | 1915.06 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14116 | NA | NA | Serum | 1923.03 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14117 | NA | NA | Serum | 1935.12 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14118 | NA | NA | Serum | 1944.57 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14119 | NA | NA | Serum | 1953.46 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14120 | NA | NA | Serum | 1962.12 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14122 | NA | NA | Serum | 1990.97 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14124 | NA | NA | Serum | 2000.28 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14126 | NA | NA | Serum | 2029.33 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14127 | NA | NA | Serum | 2036.45 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14128 | NA | NA | Serum | 2041.92 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14129 | NA | NA | Serum | 2050.28 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14130 | NA | NA | Serum | 2065.3 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14131 | NA | NA | Serum | 2079.44 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14132 | NA | NA | Serum | 2087.4 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14133 | NA | NA | Serum | 2098.68 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14134 | NA | NA | Serum | 2110 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14136 | NA | NA | Serum | 2134.89 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14137 | NA | NA | Serum | 2145.66 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14139 | NA | NA | Serum | 2168.78 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14140 | NA | NA | Serum | 2181.09 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14141 | NA | NA | Serum | 2194.14 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14142 | NA | NA | Serum | 2202.13 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14143 | NA | NA | Serum | 2226.1 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14144 | NA | NA | Serum | 2236.48 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14145 | NA | NA | Serum | 2246.03 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14146 | NA | NA | Serum | 2261.33 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14148 | NA | NA | Serum | 2270.11 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14149 | NA | NA | Serum | 2284.19 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14150 | NA | NA | Serum | 2291.61 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14151 | NA | NA | Serum | 2302.52 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14152 | NA | NA | Serum | 2309.6 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14153 | NA | NA | Serum | 2319.75 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14155 | NA | NA | Serum | 2374.11 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14156 | NA | NA | Serum | 2381.51 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14158 | NA | NA | Serum | 2407.58 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14159 | NA | NA | Serum | 2425.66 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14160 | NA | NA | Serum | 2441.68 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14161 | NA | NA | Serum | 2457.85 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14165 | NA | NA | Serum | 2547.82 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14166 | NA | NA | Serum | 2568.39 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14167 | NA | NA | Serum | 2581.12 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14168 | NA | NA | Serum | 2590.93 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14169 | NA | NA | Serum | 2598.8 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14170 | NA | NA | Serum | 2614.92 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14171 | NA | NA | Serum | 2628.53 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14172 | NA | NA | Serum | 2645.73 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14173 | NA | NA | Serum | 2661.89 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14179 | NA | NA | Serum | 2738.96 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14180 | NA | NA | Serum | 2752.7 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14181 | NA | NA | Serum | 2768.93 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14183 | NA | NA | Serum | 2797.85 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14185 | NA | NA | Serum | 2830.42 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14188 | NA | NA | Serum | 2913.13 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14196 | NA | NA | Serum | 3102.33 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14197 | NA | NA | Serum | 3169.15 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14198 | NA | NA | Serum | 3177.41 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14199 | NA | NA | Serum | 3192.36 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14209 | NA | NA | Serum | 3285.31 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14211 | NA | NA | Serum | 3304.01 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14214 | NA | NA | Serum | 3320.99 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14215 | NA | NA | Serum | 3339.94 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14216 | NA | NA | Serum | 3390.86 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14217 | NA | NA | Serum | 3409.35 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14220 | NA | NA | Serum | 3516.41 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14221 | NA | NA | Serum | 3534.25 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14222 | NA | NA | Serum | 3551.67 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14223 | NA | NA | Serum | 3706.99 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14224 | NA | NA | Serum | 3797.42 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14225 | NA | NA | Serum | 3822.52 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14226 | NA | NA | Serum | 3838.14 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14228 | NA | NA | Serum | 3961.49 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14229 | NA | NA | Serum | 3968.83 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14230 | NA | NA | Serum | 3976.47 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14231 | NA | NA | Serum | 3984.71 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14233 | NA | NA | Serum | 3992.66 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14234 | NA | NA | Serum | 4008.74 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14236 | NA | NA | Serum | 4073.65 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14237 | NA | NA | Serum | 4085.79 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14240 | NA | NA | Serum | 4149.54 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14247 | NA | NA | Serum | 4237.13 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14250 | NA | NA | Serum | 4286.89 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14251 | NA | NA | Serum | 4292.48 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14252 | NA | NA | Serum | 4298.29 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14253 | NA | NA | Serum | 4304.27 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14254 | NA | NA | Serum | 4314.16 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14255 | NA | NA | Serum | 4319.57 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14256 | NA | NA | Serum | 4320.42 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14257 | NA | NA | Serum | 4321.32 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14258 | NA | NA | Serum | 4327.41 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14259 | NA | NA | Serum | 4451.95 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14260 | NA | NA | Serum | 4480.21 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14262 | NA | NA | Serum | 4651.99 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14263 | NA | NA | Serum | 4792.96 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14264 | NA | NA | Serum | 4809.18 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14266 | NA | NA | Serum | 4993.25 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14267 | NA | NA | Serum | 5008.32 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14268 | NA | NA | Serum | 5022.55 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14269 | NA | NA | Serum | 5026.15 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14270 | NA | NA | Serum | 5032.97 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14271 | NA | NA | Serum | 5049.86 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14272 | NA | NA | Serum | 5149.58 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14273 | NA | NA | Serum | 5163.83 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14274 | NA | NA | Serum | 5174.29 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14278 | NA | NA | Serum | 5346.44 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14280 | NA | NA | Serum | 5358.43 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14297 | NA | NA | Serum | 8597.13 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |
| CancerPDF_ID14298 | NA | NA | Serum | 9287.29 | MALDI-TOF | Gastric cancer | Upregulated in cancer vs healthy | 26376850 |